Clinical Trial Update: the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC. [NA]

View source ↗

Summary

This clinical trial compares Grazoprevir/Elbasvir plus TACE to TACE alone in patients with non-resectable HCV-associated hepatocellular carcinoma. The goal is t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Hepatocellular Carcinoma

Drugs mentioned

• Grazoprevir/Elbasvir

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: HCV, HCC | NA | Status: UNKNOWN